Prasterone Micronization for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Prasterone (5-dehydroepiandrosterone) has poor bioavailability and variability, making it challenging to develop effective and scalable pharmaceutical formulations that comply with regulatory standards.
Innovation Solution
Micronization of prasterone followed by coating with a durable liquid vehicle, such as tocopherol or fish oil, to increase bioavailability and stability, allowing for standard analytical characterization and commercial-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large doses of prasterone are administered to improve bioavailability, then bioavailability increases, but adverse side effects may precipitate
Solution Approach 1:
The patent changes the physical parameters of prasterone by reducing particle size through micronization and controlling crystallization conditions to produce specific crystal forms (needles or leaflets) with controlled size distributions. This increases surface area and dissolution rate, improving bioavailability without requiring large doses, thereby avoiding adverse side effects.
Solution Approach 2:
The patent segments the prasterone into fine micronized particles with controlled size distributions (e.g., D10, D50, D90 specifications). This segmentation increases the total surface area for dissolution, improving bioavailability while allowing use of lower doses that avoid adverse effects.
2Reliability
If non-oral delivery routes are used to improve bioavailability, then bioavailability increases, but manufacturing complexity increases
Solution Approach 1:
The patent modifies the physical parameters of prasterone through micronization and crystal form control to enhance its properties for oral administration. By optimizing particle size, surface area, and crystal structure, the patent achieves improved bioavailability through the simple oral route without requiring complex non-oral delivery systems.
3Reliability
If alpha cyclodextrin clathrate method is used to improve bioavailability, then bioavailability increases, but the method requires specialized high-energy vibrational micromilling equipment not suitable for commercial scale
Solution Approach 1:
The patent employs conventional crystallization techniques and controlled cooling methods to produce micronized prasterone with desired crystal forms. These are standard industrial processes that can be scaled to commercial production, unlike the specialized high-energy vibrational micromilling required by the cyclodextrin clathrate method.
Solution Approach 2:
The patent uses controlled crystallization as an intermediary process to transform prasterone into specific crystal forms with improved bioavailability. This conventional crystallization approach serves as a mediator between the raw material and the final therapeutic product, enabling commercial-scale production without requiring specialized equipment.
4Reliability
If alpha cyclodextrin clathrate method is used to improve bioavailability, then bioavailability increases, but the resulting material has no definite X-ray diffraction fingerprint making characterization impossible
Solution Approach 1:
The patent produces prasterone with well-defined crystal structures (needles or leaflets) that exhibit characteristic X-ray diffraction patterns. By controlling crystallization conditions and particle size parameters, the patent ensures the resulting material has a definite crystallographic fingerprint, enabling accurate characterization and quality control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly enhances prasterone's oral bioavailability and reduces variability, enabling the production of a stable and effective oral dosage form that meets regulatory standards.
Implementation Method 1
Micronization of prasterone followed by coating with a durable liquid vehicle
Implementation Method 2
coating with a durable liquid vehicle, such as tocopherol or fish oil, to increase bioavailability and stability
Data Source
AI summary
A way to formulate prasterone to both increase its oral bioavailability, and decrease the variability of its oral bioavailability.In contrast to the approach taught by the prior art, the instant approach is amenable to scale-up to commercial scale. Further, the resulting product is amenable to analysis using standard, known quantitative analytical techniques; thus, unlike the prior art approach, the instant approach may be used to manufacture a product in conformity with applicable regulatory standards.